Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 14/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.40 |
| ▸ | TEC | P42680 | 1/20 | 0.40 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7550529 | 0.84 | PTPN1 (0.50) | MAOBPTPN1ALOX5APTECNR4A2 | |
| SCHEMBL7551490 | 0.82 | PPARA (0.60) | MAOBPTPN1MAOAFFAR1 | |
| SCHEMBL7556674 | 0.79 | MAOB (0.48) | MAOBPTPN1ALOX5AP | |
| SCHEMBL7556111 | 0.78 | PPARG (0.58) | MAOBPTPN1 | |
| SCHEMBL7556358 | 0.77 | PTPN1 (0.47) | MAOBPTPN1MAOATEC | |
| SCHEMBL7556849 | 0.77 | MAOB (0.52) | MAOBPTPN1MAOATEC | |
| SCHEMBL7069505 | 0.75 | ITGB1 (0.43) | MAOBALOX5AP | |
| SCHEMBL20377560 | 0.74 | NR4A2 (0.60) | MAOBPTPN1MAOANR4A2 | |
| SCHEMBL7550100 | 0.74 | PPARA (0.60) | MAOBPTPN1MAOAFFAR1 | |
| SCHEMBL7069252 | 0.73 | MAOB (0.44) | MAOBALOX5APFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032330-A1 | Propionic acid derivatives | NOMURA YUTAKA (JP) | 2002-03-14 | — | — | US | disclosed |
| EP-0994095-A1 | PROPIONIC ACID DERIVATIVES | NIPPON CHEMIPHAR CO., LTD. (JP) | 2000-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032330-A1 | Propionic acid derivatives | ABAT, ACAT1, PDXK | MAOB 1256/4885PTPN1 1696/4885ALOX5AP 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.